|
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer Clinical research trials and Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer. Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer clinical trial. Participants frequently get the best healthcare available for their Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer  Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
For Condition: Carcinoma, Non-Small-Cell Lung
Status: No longer recruiting
Sponsor(s): Telik ,
Synopsis: The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Histologic or cytologic diagnosis of non-small cell lung carcinoma - Progressed while on or after treatment on platinum-based regimen - Patients may not have had more than one prior cytotoxic chemotherapy regimen - Stage IV or IIIB - Age at least 18 years - Adequate liver and kidney function - Adequate bone marrow function Exclusion Criteria: - Pregnancy or lactation - Unstable medical conditions - Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286 - CNS metastasis unless controlled by treatment
Total Enrollment: 40
Location and Contact Information:
UCLA Medical Center
Los Angeles, California, 90095
United States
M.D. Anderson Cancer Center
Houston, Texas, 77030
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
Additional Information:
Study ID Numbers: TLK286.2014;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040638
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Comparative Trial of Pivanex and Docetaxel vs Docetaxel Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer
2. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
3. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
4. Safety and efficacy of ABR-217620 in patients with advanced non-small cell lung cancer.
5. Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients with Stage III Non-Small Cell Lung Cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
